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Abstract
Glutamate transporters are essential for terminating synaptic excitation and for maintaining extracellular glutamate concentrations below
neurotoxic levels. These transporters also mediate a thermodynamically uncoupled chloride flux, activated by two of the molecules they
transport, sodium and glutamate. Five eukaryotic glutamate transporters have been cloned and identified. They exhibitf50% identity and
this homology is even greater at the carboxyl terminal half, which is predicted to have an unusual topology. Determination of the topology
shows that the carboxyl terminal part contains several transmembrane domains separated by two reentrant loops that are in close proximity to
each other. We have identified several conserved amino acid residues in the carboxyl terminal half that play crucial roles in the interaction of
the transporter with its substrates: sodium, potassium and glutamate. The conformation of the transporter gating the anion conductance is
different from that during substrate translocation. However, there exists a dynamic equilibrium between these conformations.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Glutamate is the predominant excitatory neurotransmitter
in the central nervous system. Glutamate transporters
remove the transmitter from the cleft and maintain its
extracellular concentrations below neurotoxic levels [1–5].
In addition, at some synapses, glutamate transporters play
an important role in limiting the duration of synaptic
excitation [6–9]. Glutamate uptake is an electrogenic proc-
ess [10,11] in which the transmitter is cotransported with
three sodium ions and a proton [3,12] followed by counter-
transport of a potassium ion [13–15]. In addition to this
coupled flux, glutamate transporters mediate a thermody-
namically uncoupled chloride flux, activated by two of the
molecules they transport: sodium and glutamate [16,17].
This indicates the existence of a tight link between gating of
the anion conductance and permeation of glutamate. It has
been suggested that this capacity for enhancing chloride
permeability could alter neuronal excitability [17].
2. The glutamate transporter family: cloning and
purification
Transporters for many neurotransmitters were cloned on
the assumption that they are related to the GABA [18] and
norepinephrine [19] transporters [20–22]. This approach
was unsuccessful for the glutamate transporter. Three
different glutamate transporters were cloned using different
approaches: GLAST [23], GLT-1 [24] and EAAC-1 [25].
The former two appear to be of glial [23,24,26,27], the
latter of neuronal origin [25,28] and the same is true for
the later cloned EAAT-4 [17]. Indeed, these transporters
are not related to the above superfamily [23–25]. On the
other hand, they are very similar to each other, displaying
f50% identity andf60% similarity. They are also related
to the proton-coupled glutamate transporter from E. coli
and other bacteria (glt-P, [29]) and the dicarboxylate
transporter (dct-A, [30]) of Rhizobium meliloti. In these
cases the identities are around 25–30%. It has been shown
that the glutamate transporter family also encodes sodium-
dependent transporters that do not use dicarboxylic acids
as substrates, but rather neutral amino acids. These trans-
porters are named ASCT-1 [31,32] and ASCT-2 [33,34].
The three human homologues of the rat and rabbit gluta-
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mate transporters have been cloned [35], as have two
novel subtypes that are characterised by a large sub-
strate-induced chloride current [17,36]. A smaller sub-
strate-gated anion current, which is not thermodynamically
coupled to glutamate transport, has been observed in
several of the other subtypes as well [16] and also in
ASCT-1 [37].
GLT-1 was reconstituted and purified [26,38] and it has
573 amino acids and a relative molecular mass of 64 kDa, in
good agreement with the value of 65 kDa of the purified and
deglycosylated transporter [26].
3. Secondary structure and proximity relations
Hydropathy plots are relatively straightforward at the
amino terminal side of the protein and the three different
groups, which originally cloned GLAST-1, GLT-1 and
EAAC-1, have predicted six transmembrane a-helices at
very similar positions [23–25]. On the other hand, there is
much more ambiguity at the carboxyl side where zero [23],
two [24] or four [25]a-helices have been predicted. In the
last years, attempts have been made to determine the top-
ology of the glutamate transporters experimentally. Studies
of the highly conserved carboxyl terminal half of the
glutamate transporters indicate a nonconventional topology
(Fig. 1A) containing two reentrant loops, two transmem-
brane domains (7 and 8) long enough to span the membrane
as a-helices as well as an outward-facing hydrophobic
linker [39–41]. Another study arrives at a somewhat differ-
ent model including the assignment of transmembrane
domain 7 as a reentrant loop [42]. These models disagree
only on the accessibility of only one of the engineered
cysteines to impermeant sulfhydryl reagents [41,43].
Accessibility studies have shown that cysteine residues
introduced at positions 364 and 440 of GLT-1, located on
reentrant loops I and II, respectively, react with the imper-
meant sulfhydryl reagent MTSET added from the extra-
cellular side [41,44]. Substrates and nontransportable
analogues partially protected against the modification of
cysteines introduced at these positions. Therefore, we have
suggested that positions 364 and 440 may be close in the
three-dimensional structure of the protein [41]. To verify
this prediction and to obtain the first information regarding
the tertiary structure of the carboxyl-terminal half of the
glutamate transporters, we set out to determine proximity
relations between the different structural elements in this
region. Two types of functional assays were used to infer
proximity of engineered cysteine pairs. We identified two
cysteine pairs, A412C/V427C and A364C/S440C, which
behave as if they are close in space. The data provide
evidence that the two oppositely oriented reentrant loops
are spatially close to one another (Fig. 1B and Ref. [45]).
4. Structure–function relations of the glutamate
transporters
Substrate-induced conformational changes in the GLT-1
transporter have been detected, as revealed by the altered
accessibility of trypsin sensitive sites to the protease [46].
These experiments indicate that lithium can occupy at least
one of the sodium ion binding sites and also that there are at
least two transporter-glutamate bound states [46]. However,
lithium by itself cannot support coupled transport, so one of
the sodium binding sites in GLT-1 is specific; lithium cannot
bind to it.
Two adjacent amino acid residues of GLT-1 located in
transmembrane domain 7, tyrosine-403 and glutamate-404,
Fig. 1. Topology and proximity in the carboxyl-terminal half with the
position of identified substrate interacting residues indicated. Topological
model of the carboxyl-terminal half determined by accessibility to mutated
cysteines (A) and a refined model determined by proximity of engineered
cysteine pairs (B). The figure is adapted from Ref. [41] where the first five
transmembrane domains also are shown. The structural elements in the
carboxyl-terminal half include, three membrane-spanning a-helical trans-
membrane domains (6, 7 and 8) that are separated by two-reentrant loops
(I and II) and a hydrophobic linker (horizontal box). (A) Residues that are
involved in interactions with substrates and the non-transportable substrate-
analogue dihydrokainate (DHK) are indicated, as well as the residues,
A364, A412, V427 and S440 that are close in space (see B). Indicated is
also residue 451C in the linker, which upon chemical modification leaves
the uncoupled anion conductance intact but results in abolishment of the
coupled uptake. (B) Two cysteine-pairs, S440C/A364C and V427C/A412C,
can form a disulfide bond and must be close to each other in space [45].
B.I. Kanner, L. Borre / Biochimica et Biophysica Acta 1555 (2002) 92–95 93
appear to be involved in potassium binding [15,47] and
are close to one of the sodium binding sites (Ref. [47]; c.f.
Fig. 1A). Because of the sequential nature of the transport
process (Refs. [13–15]; c.f. Fig. 2), mutations in these
residues cause the transporter to be locked in an obligatory
exchange mode [15,47]. Moreover, tyrosine-403 behaves as
if it is alternately accessible to either side of the membrane
[48]. Analysis of GLT-1 mutants where serine-440, located
in one of the reentrant loops, has been mutated indicates that
at least part of this loop is crucial for the coupling of sodium
and glutamate fluxes and that it is close to the glutamate
binding site [44]. When serine-440 is changed to glycine, the
GLT-1 mutant catalyses coupled transport in the presence of
lithium, as if the specific sodium site now has become more
promiscuous; the transporter can now accept lithium at all
three sites [44]. Glycine occupies the corresponding position
(G410) in the glutamate transporter EAAC-1. This trans-
porter is able to catalyze uptake of glutamate in the sole
presence of lithium [49]. Importantly, the reciprocal EAAC-1
mutant, G410S, has lost the ability of lithium to support
uptake, but sodium is still able to so [49]. Another EAAC-1
mutant, T370S, has the same phenotype as G410S [49]. It
appears that this conserved threonine (which corresponds to
T400 in GLT-1; c.f. Fig. 1A) controls the selectivity of one
of the promiscuous sodium sites; mutation to serine causes
the site to become sodium-selective and lithium can no
longer support coupled uptake.
We have identified an arginine residue that controls the
binding of the gamma-carboxyl group of glutamate [50].
We reasoned that mutation of this arginine in a glutamate
transporter that also transports a non-dicarboxylic acid
substrate might leave the transport of this latter substrate
intact. It was shown that EAAT-3, the human homologue of
EAAC-1, also exhibits considerable transport of cysteine
[51]. We have found that mutation of the equivalent
arginine-447 of EAAC-1 to neutral or negative amino acid
residues completely abolishes transport of L-glutamate and
D- and L-aspartate, without impairing cysteine transport.
Surprisingly, this cysteine transport is electroneutral rather
than electrogenic. This appears to be due to a defective
interaction with potassium [50]. We propose that arginine-
447, by sequentially participating in the binding of gluta-
mate and potassium, is enabling the coupling of their fluxes
[50]. The hypothetical scheme shown in Fig. 2 illustrates a
possible scenario whereby this may be happening. Gluta-
mate-374 is the EAAC-1 equivalent of glutamate-404 of
GLT-1, shown to be crucial for interaction of the transporter
with potassium [15]. Arginine-447 could sequentially inter-
act with the endogenous glutamate-374 (in the unloaded
transporter) or with the exogenous glutamate—the substrate
to be transported (in the glutamate loaded form of the
transporter). After release of glutamate on the inside, a
potassium ion takes the place of the arginine cation in
forming an ion pair with glutamate-374. After translocation
of the potassium-loaded transporter back to the outside,
potassium dissociates and arginine-447 takes its place
again. In a mutant where this arginine is replaced, it is
possible that glutamate-374 interacts with other residues of
the transporter such that the potassium ion cannot approach
it any more. This mutant can still recognise and transport
cysteine. However, because of the defective interaction
with potassium, the transporter would be locked in the
exchange mode—only the lower half cycle would operate
(Fig. 2). Obviously this is only a framework for future
experimentation to unravel the coupling mechanism in
glutamate transporters.
5. Relation between coupled and uncoupled fluxes
In addition to the ion-coupled glutamate translocation,
glutamate transporters mediate a thermodynamically un-
coupled chloride flux. It is activated by two of the molecules
they transport, sodium and glutamate [16,17]. In a very
recent study [49], we have reported that in EAAC-1, lithium
can replace sodium in the coupled uptake but not in its
capacity to gate the glutamate-dependent anion conduc-
tance. This finding suggests that the conformation gating
the anion conductance may be different from that during
substrate translocation. If this idea is correct, it should be
possible to selectively perturb one of the two fluxes medi-
ated by the glutamate transporters. Indeed, analysis of a
mutant with a cysteine residue introduced in the hydro-
phobic linker region, I421C (corresponding to position 451
in GLT-1; c.f. Fig. 1A), reveals that the coupled uptake in
this mutant is very sensitive to sulfhydryl reagents [52].
Strikingly, the substrate-induced anion conductance is not
Fig. 2. Possible steps of arginine-447 interaction with glutamate and
potassium. In its empty configuration Arginine-447 and Glutamate-374
interact via ion-pairing TR447 +  E374. Glutamate
will take the place of
residue 374 and will coordinate to Arginine-447 (TR447 +  Glu). In the
absence of glutamate (after glutamate debinding), potassium can take the
place of residue R447 and will form an ion pair with Glutamate-374,
whereupon the transporter reorients with the potassium ion. Further details
are provided in the text. Reprinted from Ref. [55].
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affected at all by the sulfhydryl reagents [52]. Similar
observations have been made on single cysteine mutants
of the transporter EAAT-1/GLAST-1 at positions corre-
sponding to positions 447 [53] and 450 [54] of GLT-1.
Under conditions where the uncoupled current is dominant,
sulfhydryl reagents cause a more than fourfold stimulation
of this current [52]. Thus, the modification of the cysteine
introduced at position 421 impacts the coupled but not the
uncoupled flux. Although both fluxes are activated by
substrate, they behave as independent processes that are in
dynamic equilibrium [52].
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